Fatty Amides Group
These substances were identified for action under the Chemicals Management Plan (CMP). This screening assessment focuses on 3 of 12 substances referred to collectively as the Fatty Amides Group.
|Substance group||CAS RN||Common name||DSL name||Public comments on the draft screening assessment||Final screening assessment||Conclusion on section 64 criteria||Follow-up activities|
|Fatty Amides Group||112-84-5||Erucamide||13-Docosenamide, (Z)-||HTML||HTML||Does not meet||None planned at this time|
|68784-17-8Footnote a||IODA reaction products with TEPA||Isooctadecanoic acid, reaction products with tetraethylenepentamine|
|April 27, 2019||Publication of the final screening assessment. The related notice was published in the Canada Gazette, Part I: Vol. 153, No. 17|
|February 24, 2018||Publication and start of 60-day public comment period on the draft screening assessment. The related notice was published in the Canada Gazette, Part I: Vol. 152, No. 8.|
Nine other substances were identified as being part of the Fatty Amides Group at the outset of the third phase of the CMP. Five of these substances (CAS RNs 68478-81-9, 71820-35-4, CDSL 11053-1, CDSL 11555-8 and CDSL 11557-1) were subsequently determined to be of low concern to both human health and the environment, through other approaches. Conclusions for these 5 substances are provided in the Screening Assessment for the Rapid Screening of Substances with Limited General Population Exposure. The remaining 4 other substances in this group (CAS RNs 120-40-1, 142-78-9, 68153-35-5 and 68603-42-9) were placed into other substance groups, to which they are more appropriately suited based on scientific considerations. Conclusions for 3 substances (CAS RNs 120-40-1, 142-78-9 and 68603-42-9) will be provided in the upcoming Alkanolamines and Fatty Alkanolamides Group assessment, while the proposed conclusion for 1 substance (CAS RN 68153-35-5) will be provided in a future screening assessment.
Report a problem or mistake on this page
- Date modified: